Inclusion Criteria:

- Patient must have malignancy with metastatic or recurrent diseases.

- Patient must have a minimum of thirteen days period elapsed from any previous
chemotherapy or radiotherapy and all treatment-related toxicities subsided.

- Patient must have at least 2 courses of chemotherapy treatment left, and a minimum of
13 days between the administration of the last dose of the chemotherapy with PG2 and
the start of the next course of chemotherapy.

- Performance status is 0-2 by ECOG scale.

- Patient's compliance and geographic proximity that allow adequate follow up.

- Adequate bone marrow function before the chemotherapy

- Adequate liver and renal function before the chemotherapy

- Written informed consent from patients

- Woman with childbearing potential should use contraception method through the whole
PG2 treatment course.

- After the previous course of chemotherapy, the nadir of WBC dropped between 1000 to
3000/ mm3 (for phase II only).

Exclusion Criteria:

- PG2 skin test is positive.

- Active infection

- Breast feeding

- Prior radiotherapy more than 30% of the bone marrow involved.

- Pregnant woman

- Bone marrow transplantation or brain disease